Evolution of Network Biomarkers from Early to Late Stage Bladder Cancer Samples

<table class="table-group" id="tab6"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left">Rank</td><td align="center">Term</td><td align="center">Count</td><td align="center">Symbol</td><td align="center"><i>P</i> value</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left">1</td><td align="center">hsa03010:Ribosome</td><td align="center">4</td><td align="center">CUL3, CUL5, BRCA1, and CUL1</td><td align="center">1.4<i>E − </i>3</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

The pathways analysis for 18 significant proteins in early and late stage bladder cancer carcinogenesis.

BioMed Research International

tab6

Table 6

Table 6: Evolution of Network Biomarkers from Early to Late Stage Bladder Cancer Samples 